Tombal, B. F., Freedland, S. J., Armstrong, A. J., Beer, T. M., Stenzl, A., Sternberg, C. N., … Saad, F. (2020). 665P Impact of enzalutamide on patient-reported fatigue in hormone-sensitive prostate cancer (HSPC) or castration-resistant prostate cancer (CRPC). In Annals of Oncology (Vol. 31, pp. S536–S537). Elsevier BV. https://doi.org/10.1016/j.annonc.2020.08.924

Tombal, B. F., S. J. Freedland, A. J. Armstrong, T. M. Beer, A. Stenzl, C. N. Sternberg, M. Hussain, et al. “665P Impact of enzalutamide on patient-reported fatigue in hormone-sensitive prostate cancer (HSPC) or castration-resistant prostate cancer (CRPC).” In Annals of Oncology, 31:S536–37. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.924.

Tombal BF, Freedland SJ, Armstrong AJ, Beer TM, Stenzl A, Sternberg CN, et al. 665P Impact of enzalutamide on patient-reported fatigue in hormone-sensitive prostate cancer (HSPC) or castration-resistant prostate cancer (CRPC). In: Annals of Oncology. Elsevier BV; 2020. p. S536–7.

Tombal, B. F., et al. “665P Impact of enzalutamide on patient-reported fatigue in hormone-sensitive prostate cancer (HSPC) or castration-resistant prostate cancer (CRPC).” Annals of Oncology, vol. 31, Elsevier BV, 2020, pp. S536–37. Crossref, doi:10.1016/j.annonc.2020.08.924.

Tombal BF, Freedland SJ, Armstrong AJ, Beer TM, Stenzl A, Sternberg CN, Hussain M, Ganguli A, Ramaswamy K, Bhadauria HS, Ivanescu C, Turnbull J, Holmstrom S, Saad F. 665P Impact of enzalutamide on patient-reported fatigue in hormone-sensitive prostate cancer (HSPC) or castration-resistant prostate cancer (CRPC). Annals of Oncology. Elsevier BV; 2020. p. S536–S537.